Table 3 Summary of findings
| Outcomes | Illustrative comparative risk (event/100 patient-years) (95% CI) | Rate ratio (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | |
|---|---|---|---|---|---|
| Control or gentamicin | Mupirocin | ||||
| Comparison between the mupirocin ointment group and control group | |||||
| Exit-site infection | 27.7 | 10.0 (3.6–29.1) | 0.36 (0.13–1.05) | 322 (3 studies) | ⨁◯◯◯ Very low*1 |
| Peritonitis | 29.7 | 23.2 (14.9–35.9) | 0.78 (0.50–1.21) | 322 (3 studies) | ⨁⨁◯◯*2 Low |
| Technical failure | 2.0 | 2.7 (0.5–14.4) | 1.35 (0.25–7.21) | 322 (3 studies) | ⨁⨁◯◯*3 Low |
| Comparison between the mupirocin ointment group and the gentamicin ointment group | |||||
| Exit-site infection | 28.9 | 32.9 (7.8–138.8) | 1.14 (0.27–4.81) | 214 (2 studies) | ⨁◯◯◯*4 Very low |
| Peritonitis | 32.3 | 27.4 (10.3–72.9) | 0.85 (0.32–2.26) | 335 (3 studies) | ⨁⨁◯◯*5 Low |
| Technical failure | 16.5 | 9.6 (4.6–19.8) | 0.58 (0.28–1.20) | 214 (3 studies) | ⨁⨁◯◯*6 Low |